CL2008000797A1 - Composicion farmaceutica liquida que comprende una sal de 4-(2-(4-metilfenilsulfanil)fenil)piperidina seleccionada entre la sal de adicion de acido dl-lactico, glutarico, l-aspartico y glutamico; uso de dicha composicion para tratar trastornos del es - Google Patents

Composicion farmaceutica liquida que comprende una sal de 4-(2-(4-metilfenilsulfanil)fenil)piperidina seleccionada entre la sal de adicion de acido dl-lactico, glutarico, l-aspartico y glutamico; uso de dicha composicion para tratar trastornos del es

Info

Publication number
CL2008000797A1
CL2008000797A1 CL200800797A CL2008000797A CL2008000797A1 CL 2008000797 A1 CL2008000797 A1 CL 2008000797A1 CL 200800797 A CL200800797 A CL 200800797A CL 2008000797 A CL2008000797 A CL 2008000797A CL 2008000797 A1 CL2008000797 A1 CL 2008000797A1
Authority
CL
Chile
Prior art keywords
salt
methylphenylsulphanil
aspartico
glutaric
lactic
Prior art date
Application number
CL200800797A
Other languages
English (en)
Inventor
Gudrun Stensbol Tine Lasskogen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CL2008000797A1 publication Critical patent/CL2008000797A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CL200800797A 2007-03-20 2008-03-19 Composicion farmaceutica liquida que comprende una sal de 4-(2-(4-metilfenilsulfanil)fenil)piperidina seleccionada entre la sal de adicion de acido dl-lactico, glutarico, l-aspartico y glutamico; uso de dicha composicion para tratar trastornos del es CL2008000797A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200700423 2007-03-20
PCT/DK2007/050076 WO2007144006A1 (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
DKPA200701790 2007-12-14

Publications (1)

Publication Number Publication Date
CL2008000797A1 true CL2008000797A1 (es) 2008-09-26

Family

ID=39327217

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800797A CL2008000797A1 (es) 2007-03-20 2008-03-19 Composicion farmaceutica liquida que comprende una sal de 4-(2-(4-metilfenilsulfanil)fenil)piperidina seleccionada entre la sal de adicion de acido dl-lactico, glutarico, l-aspartico y glutamico; uso de dicha composicion para tratar trastornos del es

Country Status (27)

Country Link
US (1) US20100105730A1 (es)
EP (2) EP2388004A1 (es)
JP (1) JP5301474B2 (es)
KR (1) KR20090130000A (es)
AR (1) AR065796A1 (es)
AT (1) ATE526966T1 (es)
AU (1) AU2008228637B2 (es)
BR (1) BRPI0808820A2 (es)
CA (1) CA2684592C (es)
CL (1) CL2008000797A1 (es)
CO (1) CO6220958A2 (es)
CY (1) CY1112285T1 (es)
DK (1) DK2129377T3 (es)
EA (1) EA019695B1 (es)
ES (1) ES2373275T3 (es)
HK (1) HK1140949A1 (es)
HR (1) HRP20110844T1 (es)
IL (1) IL200959A (es)
MX (1) MX2009009388A (es)
MY (1) MY148695A (es)
NZ (1) NZ579717A (es)
PL (1) PL2129377T3 (es)
PT (1) PT2129377E (es)
RS (1) RS52050B (es)
SI (1) SI2129377T1 (es)
TW (1) TWI405588B (es)
WO (1) WO2008113358A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
SI2167085T1 (sl) * 2007-06-15 2014-05-30 H. Lundbeck A/S 4-(2-(4-metilfenilsulfanil)fenil)piperidin za zdravljenje sindroma razdraĺ˝ljivega äśrevesja (ibs)
WO2010121621A1 (en) 2009-04-24 2010-10-28 H. Lundbeck A/S Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
MY162392A (en) 2010-04-30 2017-06-15 Takeda Pharmaceuticals Co Enteric tablet
EP2564837B1 (en) 2010-04-30 2019-01-30 Takeda Pharmaceutical Company Limited Enteric tablet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10163326A1 (de) * 2001-07-30 2003-02-27 Disetronic Licensing Ag Verabreichungsgerät mit Dosiervorrichtung
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US6957752B2 (en) * 2001-10-16 2005-10-25 Medical Instill Technologies, Inc. Dispenser with sealed chamber and one-way valve for providing metered amounts of substances
DE10202367A1 (de) 2002-01-23 2003-09-25 Duerr Dental Gmbh Co Kg Applikator für flüssige oder viskose Substanzen
SI1626720T1 (sl) * 2003-04-04 2008-12-31 Lundbeck & Co As H Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina
EP2044020B1 (en) * 2006-06-16 2011-05-04 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
KR101367136B1 (ko) * 2007-07-27 2014-02-25 삼성디스플레이 주식회사 유기 발광 표시 장치 및 이의 제조 방법

Also Published As

Publication number Publication date
ES2373275T3 (es) 2012-02-01
DK2129377T3 (da) 2012-01-02
EA200970869A1 (ru) 2010-02-26
AU2008228637B2 (en) 2013-03-21
PL2129377T3 (pl) 2012-02-29
SI2129377T1 (sl) 2012-01-31
TWI405588B (zh) 2013-08-21
HRP20110844T1 (hr) 2011-12-31
TW200902083A (en) 2009-01-16
EP2129377B1 (en) 2011-10-05
EP2129377A1 (en) 2009-12-09
RS52050B (en) 2012-04-30
AU2008228637A1 (en) 2008-09-25
NZ579717A (en) 2012-06-29
CA2684592A1 (en) 2008-09-25
EP2388004A1 (en) 2011-11-23
IL200959A (en) 2011-12-29
US20100105730A1 (en) 2010-04-29
ATE526966T1 (de) 2011-10-15
CA2684592C (en) 2013-11-12
CY1112285T1 (el) 2015-12-09
MY148695A (en) 2013-05-31
HK1140949A1 (en) 2010-10-29
AR065796A1 (es) 2009-07-01
JP2010521500A (ja) 2010-06-24
BRPI0808820A2 (pt) 2014-08-19
IL200959A0 (en) 2010-05-17
KR20090130000A (ko) 2009-12-17
MX2009009388A (es) 2009-11-25
EA019695B1 (ru) 2014-05-30
PT2129377E (pt) 2011-12-23
WO2008113358A1 (en) 2008-09-25
CO6220958A2 (es) 2010-11-19
JP5301474B2 (ja) 2013-09-25

Similar Documents

Publication Publication Date Title
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
DOP2014000133A (es) Triazolopiridinas sustituidas
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
CL2014000732A1 (es) Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende.
AR078846A1 (es) Composicion para el tratamiento de la enfermedad de alzheimer
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
BR112012018374A2 (pt) derivados de ácido carboxílico de pirrolidina ou tiazolidina, composição farmacêutica e métodos para uso no tratamento de distúrbios metabólicos como agonistas de receptor 43 acoplado à proteína g (gpr43).
CL2008000403A1 (es) Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.
IT1402907B1 (it) Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose.
UY30410A1 (es) Aminopirazolopiridinas sustituidas y sus sales, composiciones farmaceuticas que las comprenden, metodos para prepararlas y sus usos
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
CR20120058A (es) Composiciones nuevas de 1 - [2 - (2,4-dimetil-fenilsulfanil)-fenil] piperazina
CL2008001817A1 (es) Sales piperazina, benzatina y colina en forma cristalina del acido {4,6-bis(dimetilamino-2-)4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il)acético; proceso de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades inflamatorias tales como asma, rinitis alérgica, crohn, entre otras.
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
CL2013003563A1 (es) Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma.
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
CL2008000796A1 (es) Uso de 4-(2-(4-metilfenilsulfanil)fenil)piperidina y sales de adicion de acidos de la misma para el tratamiento del adhd, melancolia, depresion o sintomas residuales de la depresion; y dicho compuesto.
BR112014027470A2 (pt) novo processo para preparação de derivados 2-(1-hidroxi-alquilo)-cromen-4-ona oticamente puros e opcionalmente substituídos e seu uso na preparação de produtos farmacêuticos.
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
CU20110233A7 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
CL2008000797A1 (es) Composicion farmaceutica liquida que comprende una sal de 4-(2-(4-metilfenilsulfanil)fenil)piperidina seleccionada entre la sal de adicion de acido dl-lactico, glutarico, l-aspartico y glutamico; uso de dicha composicion para tratar trastornos del es
FR2974729B1 (fr) Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent